Purpose/objectives: To review standard and investigational treatments in advanced renal cell carcinoma, with a focus on thalidomide.
Data sources: Published articles, conference proceedings, treatment guidelines, and textbooks.
Data synthesis: The prognosis for advanced renal cell carcinoma when treated with standard regimens is poor; therefore, new treatments are needed.
Conclusions: Treatment with thalidomide, alone and in combination with other therapies, may improve survival for patients with advanced renal cell carcinoma.
Implications for nursing: Proactive management of adverse effects associated with thalidomide, alone and in combination, may increase patient tolerance and compliance.